Toxicology study

RNS Number : 0898Y

Immupharma PLC

02 July 2008

 



For Immediate Release

2 July 2008

ImmuPharma PLC

Long term toxicology studies confirmed the safety of LupuzorTM

ImmuPharma PLC (LSE:IMM), ('ImmuPharma' or the 'Company'), the specialist drug discovery and development company, announces today LupuzorTM its treatment for Lupus, a chronic, life-threatening autoimmune disease, completed the first leg of the mandatory long term toxicology study package. International regulations require two long term toxicology studies (6 and 9 months) for drug products intended to be use chronically. ImmuPharma reports that the first study has been completed and that there was no clinical or laboratory findings suggesting any safety issues. Further, an interim analysis of the second study supported these findings. These studies were requirements from The FDA (Food and Drug Administration) in the US prior to initiating ImmuPharma's Phase III programme.

For further information please contact: 

ImmuPharma PLC:
Dimitri Dimitriou, Chief Executive Officer	[phone]
Dr Robert Zimmer, President & Chief Scientific Officer	+ 33 389 32 76 50
Richard Warr, Chairman	[phone]
Buchanan Communications	+ 44 20 7466 5000
Lisa Baderoon
Rebecca Skye Dietrich
Panmure Gordon & Co
Andrew Burnett	[phone]

For further company information, visit www.immupharma.com

 

END

 

 

MSCRBMBTMMTMTFP